// Pipeline
From viscosupplementation to regenerative care.
Our next chapter brings regenerative therapies into the same evidence-based, quality-first framework we apply today.
FIG. 04INVESTIGATIONAL
IN DEVELOPMENT
Regenerative options for joint care
We are actively evaluating regenerative therapies — including advanced biologics and biomaterials — that complement our current portfolio for osteoarthritis and chronic joint pain. As with everything we distribute, only therapies with credible evidence and quality manufacturing will move forward.
- Biologic and biomaterial candidates under evaluation
- Focus on orthopedic and rheumatologic indications
- Manufacturer partnerships under discussion
01SELECTION PRINCIPLES
01
Evidence
Peer-reviewed clinical data supporting the intended indication.
02
Quality
Manufacturers with auditable EU or equivalent quality systems.
03
Fit
Therapies that serve the specialists and patients we already support.
Get notified on pipeline updates
We'll let you know when regenerative options move toward launch.